{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:22:20Z","timestamp":1790875340553,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2314-B-002 -211"],"award-info":[{"award-number":["MOST 107-2314-B-002 -211"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["112-S0108"],"award-info":[{"award-number":["112-S0108"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the clinical outcomes and risk factors associated with progressive fibrosing interstitial lung disease (PF-ILD) in patients with primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease (pSjS-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During 2015\u20132021, pSjS patients with ILD were retrospectively identified. Patients were grouped into non-PF-ILD and PF-ILD. Demographics, laboratory data, pulmonary function tests (PFTs), images, survival outcomes were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>153 patients with SjS-ILD were reviewed, of whom 68 having primary SjS-ILD (pSjS-ILD) were classified into non-PF-ILD (n\u2009=\u200934) and PF-ILD groups (n\u2009=\u200934). PF-ILD group had persistently lower albumin levels and a smaller decline in immunoglobulin G (IgG) levels at the 3rd month of follow-up. The multivariate logistic regression analysis revealed that persistently low albumin levels were associated with PF-ILD. At the 12th month, the PF-ILD group experienced a smaller increase in FVC and a greater decline in the diffusion capacity of carbon monoxide (DLCO) than at baseline. The 3-year overall survival rate was 91.2%, and PF-ILD group had significantly poorer 3-year overall survival rate than non-PF-ILD group (82.4% vs. 100%, p\u2009=\u20090.011). Poor survival was also observed among female patients with PF-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with pSjS-ILD, the PF-ILD group had poorer 3-year survival outcomes. Persistent lower albumin level might be the risk factor of PF-ILD. Early lung function tests could be helpful for the early detection of PF-ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02562-w","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:02:05Z","timestamp":1689757325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Yu-Hsuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Jung","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Chou","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"1","key":"2562_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","volume":"22","author":"BS Kwon","year":"2021","unstructured":"Kwon BS, Choe J, Chae EJ, Hwang HS, Kim YG, Song JW. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res. 2021;22(1):282.","journal-title":"Respir Res"},{"issue":"11","key":"2562_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015\u201324.","journal-title":"Curr Med Res Opin"},{"key":"2562_CR3","doi-asserted-by":"crossref","unstructured":"Nasser M, Larrieu S, Si-Mohamed S et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J 2021;57(2).","DOI":"10.1183\/13993003.02718-2020"},{"key":"2562_CR4","doi-asserted-by":"publisher","first-page":"106579","DOI":"10.1016\/j.rmed.2021.106579","volume":"187","author":"YH Chiu","year":"2021","unstructured":"Chiu YH, Spierings J, de Jong PA, et al. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respir Med. 2021;187:106579.","journal-title":"Respir Med"},{"key":"2562_CR5","doi-asserted-by":"crossref","unstructured":"Brown KK, Martinez FJ, Walsh SLF et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020;55(6).","DOI":"10.1183\/13993003.00085-2020"},{"issue":"18","key":"2562_CR6","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing interstitial lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"2562_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000502551","volume":"98","author":"C Hyldgaard","year":"2019","unstructured":"Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E. Rheumatoid Arthritis-Associated interstitial lung disease: clinical characteristics and predictors of Mortality. Respiration. 2019;98(5):455\u201360.","journal-title":"Respiration"},{"issue":"3","key":"2562_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/BOR.0000000000000380","volume":"29","author":"C Johnson","year":"2017","unstructured":"Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2017;29(3):254\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"2562_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","volume":"201","author":"D Khanna","year":"2020","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J, Etiology. Risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6):650\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2562_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201809-1652OC","volume":"200","author":"RK Putman","year":"2019","unstructured":"Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging patterns are Associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200(2):175\u201383.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2562_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology\/European League against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: a Consensus and Data-Driven Methodology Involving Three International Patient cohorts. Arthritis Rheumatol. 2017;69(1):35\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2562_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren\u2019s syndrome: a revised version of the european criteria proposed by the american-european Consensus Group. Ann Rheum Dis. 2002;61(6):554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2562_CR13","doi-asserted-by":"publisher","unstructured":"Fraser E, St Noble V, Hoyles RK, Benamore R, Ho LP. Readily accessible CT scoring method to quantify fibrosis in IPF. BMJ Open Respir Res. 2020;7(1):e000584. https:\/\/doi.org\/10.1136\/bmjresp-2020-000584","DOI":"10.1136\/bmjresp-2020-000584"},{"issue":"3","key":"2562_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621\u201336.","journal-title":"Biochem J"},{"key":"2562_CR15","doi-asserted-by":"crossref","unstructured":"Antoniu SA. Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795\u2013802. Expert Opin Investig Drugs 2007;16(5):753\u2013756.","DOI":"10.1517\/13543784.16.5.753"},{"issue":"1","key":"2562_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4049\/jimmunol.179.1.708","volume":"179","author":"C Tabata","year":"2007","unstructured":"Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 2007;179(1):708\u201314.","journal-title":"J Immunol"},{"issue":"4","key":"2562_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","volume":"159","author":"R Vij","year":"2012","unstructured":"Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159(4):218\u201327.","journal-title":"Transl Res"},{"issue":"4","key":"2562_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.08-0754","volume":"135","author":"DA Zisman","year":"2009","unstructured":"Zisman DA, Kawut SM, Lederer DJ, et al. Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. Chest. 2009;135(4):929\u201335.","journal-title":"Chest"},{"issue":"3","key":"2562_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","volume":"42","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750\u20137.","journal-title":"Eur Respir J"},{"issue":"5","key":"2562_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","volume":"168","author":"HR Collard","year":"2003","unstructured":"Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"2562_CR21","doi-asserted-by":"publisher","unstructured":"Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580\u2013588. https:\/\/doi.org\/10.1513\/AnnalsATS.201807-443OC","DOI":"10.1513\/AnnalsATS.201807-443OC"},{"key":"2562_CR22","doi-asserted-by":"publisher","unstructured":"Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322\u20131328. https:\/\/doi.org\/10.1183\/09031936.00092309","DOI":"10.1183\/09031936.00092309"},{"key":"2562_CR23","doi-asserted-by":"publisher","unstructured":"Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al.; British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676\u20131682. https:\/\/doi.org\/10.1093\/rheumatology\/keu165","DOI":"10.1093\/rheumatology\/keu165"},{"issue":"5","key":"2562_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"2562_CR25","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/1756-185X.14023","volume":"23","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou J, Dong X, Guo X, Lu Y, Zheng Y. Risk factors for progression and prognosis of primary Sjogren\u2019s syndrome-associated interstitial lung disease in a chinese population. Int J Rheum Dis. 2020;23(12):1734\u201340.","journal-title":"Int J Rheum Dis"},{"key":"2562_CR26","doi-asserted-by":"publisher","first-page":"754851","DOI":"10.3389\/fphar.2021.754851","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Guo J, Yu D, Jie B, Zhou Y. Predictors of Mortality in Progressive Fibrosing interstitial lung Diseases. Front Pharmacol. 2021;12:754851.","journal-title":"Front Pharmacol"},{"key":"2562_CR27","doi-asserted-by":"publisher","unstructured":"Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639\u2013644. https:\/\/doi.org\/10.1164\/rccm.200403-331OC","DOI":"10.1164\/rccm.200403-331OC"},{"key":"2562_CR28","doi-asserted-by":"publisher","unstructured":"Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(6):1183\u20131188. https:\/\/doi.org\/10.1183\/09031936.00165207","DOI":"10.1183\/09031936.00165207"},{"key":"2562_CR29","doi-asserted-by":"publisher","unstructured":"Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sj?gren syndrome-associated interstitial lung disease. Sci Rep. 2021;11(1):12827. https:\/\/doi.org\/10.1038\/s41598-021-92024-2","DOI":"10.1038\/s41598-021-92024-2"},{"key":"2562_CR30","doi-asserted-by":"publisher","unstructured":"Kamiya Y, Fujisawa T, Kono M, Nakamura H, Yokomura K, Koshimizu N, et al. Prognostic factors for primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung diseases. Respir Med. 2019;159:105811. https:\/\/doi.org\/10.1016\/j.rmed.2019.105811","DOI":"10.1016\/j.rmed.2019.105811"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02562-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:02:41Z","timestamp":1689757361000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02562-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2562"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02562-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research Ethics Committee of National Taiwan University Hospital (202111037RINB) and written informed consent was waived by the Research Ethics Committee of National Taiwan University Hospital due to the retrospective observation study design. The research is performed in accordance with the Declaration of Helsinki. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}